Drug Sponsors

Pfizer, Gamida Cell ink investment and option agreement

Wednesday, August 20, 2014 01:31 PM

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

More... »


Valeant extends offer to acquire Allergan

Wednesday, August 20, 2014 01:26 PM

Valeant Pharmaceuticals International has extended the expiration of its exchange offer to acquire all outstanding shares of Allergan to 5:00 p.m., New York City time, Dec. 31. The exchange offer previously was scheduled to expire at 5:00 p.m., New York City time, Friday, Aug. 15. All other terms and conditions of the exchange offer remain unchanged.

More... »

CenterWatch

Nanotherapeutics opens new office in Maryland

Wednesday, August 20, 2014 01:17 PM

Nanotherapeutics, an integrated biopharmaceutical company with a focus on development and manufacturing, has opened a new office in Frederick, Md. The office was established to better support the company’s U.S. government contracts. With headquarters in Alachua, Fla., and a clinical team in Durham, N.C., Nanotherapeutics now has three strategically located offices.

More... »

Group of 19 institutional investors seeks support for biosimilars from top biopharma companies

Thursday, August 14, 2014 02:34 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Don’t bad mouth biosimilars—they are needed to help hold down skyrocketing drug costs.

More... »

uniQure acquires cardiology gene therapy company InoCard

Wednesday, August 13, 2014 01:11 PM

uniQure, an Amsterdam, Netherlands-based provider of human gene therapy, has acquired InoCard, a Germany-based early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

More... »

Cellular Biomedicine Group acquires Agreen Biotech

Wednesday, August 13, 2014 01:01 PM

Cellular Biomedicine Group, a California-based developer of new treatments for degenerative and cancerous diseases, has acquired China-based Agreen Biotech and its founder’s U.S. patent for $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

More... »

Oncothyreon acquires Alpine Biosciences

Wednesday, August 13, 2014 12:59 PM

Oncothyreon, a Washington-based biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, has acquired Alpine Biosciences, a Seattle, Wash.-based privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. 

More... »

Galenica lays foundation for two listed, independent companies

Wednesday, August 13, 2014 12:57 PM

The Galenica Group, a Switzerland-based healthcare group that develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks, plans to separate into two independent companies.

More... »

Marathon Pharmaceuticals opens bioscience center in Chicago

Thursday, August 7, 2014 09:00 AM

Marathon Pharmaceuticals has opened the Marathon Bioscience Center in Chicago. The facility houses the company’s research, clinical and regulatory staff, who develop and register new treatments for rare diseases.

More... »

Alvogen acquires Korean Dream Pharma for $187 million

Thursday, August 7, 2014 08:00 AM

Alvogen, an international, privately owned pharmaceuticals company, has acquired Dream Pharma of South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, the combination will create one of the largest generic pharmaceutical companies in South Korea.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs